VOQUEZNA TRIPLE PAK
Details
- Status
- Prescription
- First Approved
- 2022-05-03
- Routes
- ORAL
- Dosage Forms
- CAPSULE, TABLET, TABLET
VOQUEZNA TRIPLE PAK Approval History
What VOQUEZNA TRIPLE PAK Treats
5 indicationsVOQUEZNA TRIPLE PAK is approved for 5 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Lower Respiratory Tract Infection
- Acute Bacterial Otitis Media
- Sinusitis
- Skin and Skin Structure Infection
- Urinary Tract Infection
Drugs Similar to VOQUEZNA TRIPLE PAK
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VOQUEZNA TRIPLE PAK FDA Label Details
ProIndications & Usage
FDA Label (PDF)Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑la...
VOQUEZNA TRIPLE PAK Patents & Exclusivity
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.